Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.
Anthony LucciCarolyn S HallSapna Pradyuman PatelBoomadevi NarendranJessica B BauldryRichard E RoyalMandar KarhadeJoshua R UpshawJennifer A WargoIsabella C GlitzaMichael K K WongRodabe N AmariaHussein A TawbiAdi DiabMichael A DaviesJeffrey E GershenwaldJeffrey E LeePatrick HwuMerrick I RossPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
≥1 CTC was independently associated with melanoma relapse, suggesting that CTC assessment may be useful to identify patients at risk for relapse who could derive benefit from adjuvant therapy.